Highlights from ESMO 2024: More Intelligent Choice of Treatment in the Future

According to Daniel Heinrich, senior physician at Innlandet Hospital Trust Gjøvik, Norway, the most interesting study was as a uro-oncologist, The PEACE-3 study evaluating the addition of radium menzalutamide in first-line treatment of metastatic castration-resistant prostate cancer. Daniel Heinrich has selected three studies, all presented at ESMO 2024, for prostate cancer, bladder cancer and kidney cancer respectively. The three studies that he finds most interesting at ESMO within uro-oncology.